ADC Therapeutics SA
$ 3.86
1.31%
14 Apr - close price
- Market Cap 490,391,000 USD
- Current Price $ 3.86
- High / Low $ 3.99 / 3.83
- Stock P/E N/A
- Book Value -1.48
- EPS -1.13
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -7.06 %
- 52 Week High 4.98
- 52 Week Low 1.14
About
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Analyst Target Price
$8.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-10 | 2025-08-12 | 2025-05-05 | 2025-03-27 | 2024-11-07 | 2024-08-06 | 2024-05-06 | 2024-03-13 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.04 | -0.19 | -0.25 | -0.36 | -0.25 | -0.42 | -0.38 | -0.56 | -1.03 | -0.58 | -0.58 | -0.74 |
| Estimated EPS | -0.2983 | -0.36 | -0.39 | -0.4143 | -0.43 | -0.38 | -0.46 | -0.56 | -0.5 | -0.63 | -0.46 | -0.67 |
| Surprise | 0.2583 | 0.17 | 0.14 | 0.0543 | 0.18 | -0.04 | 0.08 | 0 | -0.53 | 0.05 | -0.12 | -0.07 |
| Surprise Percentage | 86.5907% | 47.2222% | 35.8974% | 13.1064% | 41.8605% | -10.5263% | 17.3913% | 0% | -106% | 7.9365% | -26.087% | -10.4478% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADCT
2026-04-10 22:10:50
ADC Therapeutics (NYSE: ADCT) announced its fourth quarter and full year 2025 financial results, reporting net product revenues of $22.3 million and $73.6 million, respectively, and a reduced net loss of $6.4 million for Q4 2025. The company also provided operational updates, including anticipated topline data from the LOTIS-5 Phase 3 trial in Q2 2026 and full results by year-end 2026, and highlighted its cash and cash equivalents of $261.3 million, providing an expected cash runway extending at least into 2028. Additionally, an amendment to the HealthCare Royalty financing agreement was reported, increasing strategic flexibility by reducing the change of control payment.
2026-04-10 20:09:14
ADC Therapeutics (NYSE: ADCT) announced its 2026 Annual General Meeting (AGM) will be held virtually on June 1, 2026. Shareholders will vote on 12 proposals, including the re-election of directors and auditors, and amendments to increase authorized and conditional share capital. The proxy materials also disclose executive compensation frameworks for 2025, noting a 125% AIP payout and recent RSU grants to named executives.
2026-04-10 04:09:14
The article provides news and event updates for ADCT.N (ADC Therapeutics), including recent Q4 2025 earnings reports and an upcoming investor conference schedule. Key financial data reveals a Q4 revenue beat and a cash runway expected to last into 2028. Additionally, the company is preparing for significant clinical trial results and potential regulatory approvals for its ZYNLONTA program.
2026-04-03 02:11:17
A major shareholder of ADC Therapeutics (NYSE:ADCT), Redmile Group, Llc, recently sold a significant number of shares, including 196,229 shares on March 31st and additional large blocks on April 2nd, reducing its ownership by 1.25%. Despite these insider sales totaling millions of dollars, ADCT's stock remained relatively flat, and analysts maintain a "Moderate Buy" rating with an average target price of $7.67. ADC Therapeutics is a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates for treating hematological malignancies.
2026-04-03 02:11:17
Redmile Group, a major shareholder in ADC Therapeutics (NYSE:ADCT), sold multiple blocks of ADCT stock between March 31 and April 2, totaling approximately 5.9 million shares for about $19.6 million. Despite these sales, Redmile Group still holds around 15.3 million shares. ADC Therapeutics currently trades near $3.81 and has a "Moderate Buy" consensus analyst rating with an average target of $7.67, though the company remains loss-making.
2026-04-03 02:11:17
Redmile Group, a major shareholder in ADC Therapeutics (NYSE:ADCT), sold over 2.6 million shares totaling $8.6 million on April 2nd, 2026, reducing its stake by 17.22%. Despite the insider selling, ADC Therapeutics maintains a "Moderate Buy" rating from analysts with an average target price of $7.67. The company, a clinical-stage biopharmaceutical firm focusing on antibody-drug conjugates, has seen mixed institutional trading and currently trades at $3.81 with a market cap of $483.39 million.
